AMPE - Ampio posts early positive data from phase 1 COVID-19 respiratory distress trial

Ampio Pharma (AMPE) announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion vs standard of care for patients with COVID-19 respiratory distress (AP-014).An independent statistical analysis revealed patients administered Ampion needed less oxygen and showed greater clinical improvement than those receiving the standard of care for COVID-19 respiratory complications.Ampion improved all-cause mortality in COVID-19 patients with respiratory distress compared to standard of care, and there have been no drug-related serious adverse events, Ampio said.The company now plans to increase the number of patients in the trial from 40 to 140 and has added additional hospitals as study sites.Ampion shares up nearly 3% premarket.

For further details see:

Ampio posts early positive data from phase 1 COVID-19 respiratory distress trial